Source:http://linkedlifedata.com/resource/pubmed/id/12736111
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2003-5-8
|
| pubmed:abstractText |
This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b. The dose of bleomycin was 15 mg on days 2 and 5, of vincristine 1 mg/m(2) on days 1 and 4, of lomustine 80 mg on day 1, and of dacarbazine (DTIC) 200 mg/m(2) on days 1-5, given every 4 weeks for a minimum of two cycles. Subcutaneous (s.c.) interferon alpha-2b at a dose of 3 x 10(6) IU was initiated on day 8 of the first cycle, and continued at a dose of 6 x 10(6) IU three times per week after 6 weeks. A median of two cycles were administered to 24 patients (median age 60.5 years). None achieved an objective response (0%; 95% Confidence Interval (CI): 0-14), 2 (8.3%) remained stable, 20 showed progression, and 2 (8.3%) were invaluable. The median progression-free survival was 1.9 months (95% CI: 1.8-3.4) and overall survival 10.6 months (95% CI: 6.9-16.4). Overall survival improved with increasingly favourable pretreatment characteristics (median, 14.7 versus 6.9 versus 6.0 months for Helsinki University Central Hospital (HUCH) Working Formulation stages IVBa, IVBb and IVBc, respectively; P=0.018). Grade 3 alopecia and neurotoxicity occurred in 13% of the patients. This multicentre study did not confirm earlier reports that BOLD with human leucocyte or recombinant interferon would induce at least 15% objective responses in metastatic uveal melanoma.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Lomustine,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0959-8049
|
| pubmed:author |
pubmed-author:GoreMM,
pubmed-author:Hahka-KemppinenMM,
pubmed-author:HanssonJJ,
pubmed-author:HumbletYY,
pubmed-author:KiveläTT,
pubmed-author:KlokeOO,
pubmed-author:KruitW H JWH,
pubmed-author:KumpulainenEE,
pubmed-author:ParvinenL-MLM,
pubmed-author:PyrhönenSS,
pubmed-author:SuciuSS,
pubmed-author:VuoristoM-SMS
|
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1115-20
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12736111-Adult,
pubmed-meshheading:12736111-Aged,
pubmed-meshheading:12736111-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12736111-Bleomycin,
pubmed-meshheading:12736111-Dacarbazine,
pubmed-meshheading:12736111-Disease-Free Survival,
pubmed-meshheading:12736111-Feasibility Studies,
pubmed-meshheading:12736111-Female,
pubmed-meshheading:12736111-Humans,
pubmed-meshheading:12736111-Interferon-alpha,
pubmed-meshheading:12736111-Lomustine,
pubmed-meshheading:12736111-Male,
pubmed-meshheading:12736111-Melanoma,
pubmed-meshheading:12736111-Middle Aged,
pubmed-meshheading:12736111-Neoplasm Metastasis,
pubmed-meshheading:12736111-Prospective Studies,
pubmed-meshheading:12736111-Recombinant Proteins,
pubmed-meshheading:12736111-Treatment Outcome,
pubmed-meshheading:12736111-Uveal Neoplasms,
pubmed-meshheading:12736111-Vincristine
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
|
| pubmed:affiliation |
Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Haartmaninkatu 4, PL 220, Finland. tero.kivela@helsinki.fi
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|